NMR Spectroscopic Reference Data of Synthetic Cannabinoids Sold on the Internet.

Magn Reson Chem

Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria.

Published: January 2025

Besides classic illegal drugs, numerous designer drugs, also called new psychoactive substances (NPSs), are available on the global drug market. One of the biggest and fastest-growing substance classes comprises the synthetic cannabinoids. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 254 out of 950 monitored substances belong to this group of NPS, with 9 new cannabinoids registered for the first time in 2023. For their purchase, it is not necessary to use the dark web. Due to the structural differences compared to the illegal Δ-THC (delta-9-tetrahydrocannabinol), the legal status changes and the synthetic cannabinoids are available via clear web pages. They come as powders or dissolved and sprayed onto non-psychoactive layers such as cannabidiol hemp, industrial hemp or also on other plant material like herbal tea mixtures or dried flowers. These adulterated plant parts can be smoked as a substitute to the psychoactive and in many countries illegal Δ-THC-containing hemp. The main task of this project was to check the identity of online available synthetic cannabinoid samples and to generate experimental data using a combination of gas and liquid chromatography with mass spectrometric detection and NMR-based structure elucidation. In total, 25 substances in solid state were bought from various online shops. They turned out to be 21 synthetic cannabinoids after analysis, including 13 with no or incomplete experimental NMR data available in the literature and one, CH-PIATA, which has not been mentioned in literature yet. More than 50% of the acquired substances were falsely declared.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mrc.5498DOI Listing

Publication Analysis

Top Keywords

synthetic cannabinoids
16
synthetic
5
cannabinoids
5
nmr spectroscopic
4
spectroscopic reference
4
reference data
4
data synthetic
4
cannabinoids sold
4
sold internet
4
internet classic
4

Similar Publications

This narrative review explores the benefits and risks of cannabinoids in kidney health, particularly in individuals with pre-existing renal conditions. It discusses the roles of cannabinoid receptor ligands (phytocannabinoids, synthetic cannabinoids, and endocannabinoids) in kidney physiology. The metabolism and excretion of these substances are also highlighted, with partial elimination occurring via the kidneys.

View Article and Find Full Text PDF

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Int J Mol Sci

December 2024

Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

An impact of legalization and decriminalization of marijuana is the gradual increase in the use of cannabis for recreational purposes, which poses a potential threat to society and healthcare systems worldwide. However, the discovery of receptor subtypes, endogenous endocannabinoids, and enzymes involved in synthesis and degradation, as well as pharmacological characterization of receptors, has led to exploration of the use of cannabis in multiple peripheral and central pathological conditions. The role of cannabis in the modulation of crucial events involving perturbed physiological functions and disease progression, including apoptosis, inflammation, oxidative stress, perturbed mitochondrial function, and the impaired immune system, indicates medicinal values.

View Article and Find Full Text PDF

Motor vehicle accidents (MVA) are the leading cause of death in childhood and young adult age. One of the most important factors behind MVA is driving under the influence of alcohol (DUIA) and drugs (DUID). The importance of DUID is rising together with the increasing drug abuse.

View Article and Find Full Text PDF

In corticostriatal nerve terminals, glutamate release is stimulated by adenosine via A receptors (ARs) and simultaneously inhibited by endocannabinoids via CB receptors (CBRs). We previously identified presynaptic AR-CBR heterotetrameric complexes in corticostriatal nerve terminals. We now explored the possible functional interaction between ARs and CBRs in purified striatal GABAergic nerve terminals (synaptosomes) and compared these findings with those on the release of glutamate.

View Article and Find Full Text PDF

Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.

Pharmaceuticals (Basel)

December 2024

Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, Brazil.

Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!